Is COWZ ETF a Good Investment?
There’s a reason even Warren Buffett advocates his heirs to…
Sell
1
HOOK Quote, Financials, Valuation and Earnings
Last price:
$1.87
Seasonality move
:
-6.53%
Day range:
$1.75 - $2.14
52-week range:
$1.75 - $10.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.44x
P/B ratio:
0.30x
Volume:
402.3K
Avg. volume:
186.5K
1-year change:
-76.73%
Market cap:
$21.5M
Revenue:
$20.1M
EPS (TTM):
-$3.71
Analysts' Opinion
-
Consensus RatingHOOKIPA Pharma has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.33, HOOKIPA Pharma has an estimated upside of 817.6% from its current price of $1.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.78.
Fair Value
-
According to the consensus of 3 analysts, HOOKIPA Pharma has 817.6% upside to fair value with a price target of $16.33 per share.
HOOK vs. S&P 500
-
Over the past 5 trading days, HOOKIPA Pharma has underperformed the S&P 500 by -2.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
HOOKIPA Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
HOOKIPA Pharma revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter HOOKIPA Pharma reported revenues of $4.7M.
Earnings Growth
-
HOOKIPA Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter HOOKIPA Pharma reported earnings per share of -$1.10.
Enterprise value:
-38.3M
EV / Invested capital:
--
Price / LTM sales:
0.44x
EV / EBIT:
--
EV / Revenue:
-0.77x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.56x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-30.72%
Net Income Margin (TTM):
-86.74%
Return On Equity:
-48.48%
Return On Invested Capital:
-48.13%
Operating Margin:
-327.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $10.3M | $20.6M | $50M | $6.9M | $4.7M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$73.2M | -$70.9M | -$35.1M | -$19.8M | -$15.4M | |
| EBITDA | -$69.1M | -$65.1M | -$39.8M | -$18.5M | -$13.1M | |
| Diluted EPS | -$15.30 | -$8.31 | -$3.71 | -$1.73 | -$1.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $105.8M | $118.6M | $129.6M | $139.5M | $93.2M | |
| Total Assets | $121.3M | $142.2M | $151.5M | $164M | $109.7M | |
| Current Liabilities | $18.7M | $26.6M | $26.1M | $40.6M | $28.6M | |
| Total Liabilities | $29.1M | $34.1M | $38.2M | $69M | $37.9M | |
| Total Equity | $92.2M | $108.1M | $113.3M | $95.1M | $71.8M | |
| Total Debt | $4.2M | $4.9M | $2.2M | $1M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$46.4M | -$33.2M | -$67.3M | -$24.1M | -$17.5M | |
| Cash From Investing | -$9.6M | -$4.3M | -$614K | -$3M | -$31K | |
| Cash From Financing | $72.1M | $44.2M | $20M | -$659K | -- | |
| Free Cash Flow | -$55.9M | -$37.5M | -$67.9M | -$27.1M | -$17.5M | |
HOOK
Sector
Market Cap
$21.5M
$46.7M
Price % of 52-Week High
16.95%
46.54%
Dividend Yield
0%
0%
Shareholder Yield
-40.6%
-0.74%
1-Year Price Total Return
-76.73%
-33.88%
Beta (5-Year)
0.713
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.92
200-day SMA
Sell
Level
$5.32
Bollinger Bands (100)
Sell
Level
2.39 - 4.67
Chaikin Money Flow
Sell
Level
-196.5M
20-day SMA
Sell
Level
$1.99
Relative Strength Index (RSI14)
Sell
Level
36.63
ADX Line
Buy
Level
36.22
Williams %R
Buy
Level
-97.1429
50-day SMA
Sell
Level
$2.58
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
392.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.1326)
Sell
CA Score
(Annual)
Level (-2.25)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.2092)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Stock Forecast FAQ
In the current month, HOOK has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The HOOK average analyst price target in the past 3 months is $16.33.
-
Where Will HOOKIPA Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that HOOKIPA Pharma share price will rise to $16.33 per share over the next 12 months.
-
What Do Analysts Say About HOOKIPA Pharma?
Analysts are divided on their view about HOOKIPA Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that HOOKIPA Pharma is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is HOOKIPA Pharma's Price Target?
The price target for HOOKIPA Pharma over the next 1-year time period is forecast to be $16.33 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is HOOK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for HOOKIPA Pharma is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HOOK?
You can purchase shares of HOOKIPA Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase HOOKIPA Pharma shares.
-
What Is The HOOKIPA Pharma Share Price Today?
HOOKIPA Pharma was last trading at $1.87 per share. This represents the most recent stock quote for HOOKIPA Pharma. Yesterday, HOOKIPA Pharma closed at $1.78 per share.
-
How To Buy HOOKIPA Pharma Stock Online?
In order to purchase HOOKIPA Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Why Did Buffett Sell So Much Last Year?
In 2024, value investing legend Warren Buffett did the seemingly…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 14
Intra-Cellular Therapies [ITCI] is down 0.26% over the past day.
Sell
30
ESTA alert for Jan 14
Establishment Labs Holdings [ESTA] is down 1.51% over the past day.
Buy
72
DJT alert for Jan 14
Trump Media & Technology Group [DJT] is down 8.25% over the past day.
